Table 3. Antithrombotic Treatment Before, During and Following PCI.
| Antithrombotic treatments | Antithrombotic treatment start |
Overall, n (%) | ||
|---|---|---|---|---|
| Pre-PCI, n (%) | Peri-PCI and post-PCI, n (%) | Discharge, n (%) | ||
| Clopidogrel | 31 (11.4%) | 156 (57.4%) | 192 (70.6%) | 187 (68.8%) |
| Ticagrelor | 70 (25.7%) | 5 (1.8%) | 68 (25.0%) | 75 (27.6%) |
| Prasugrel | 10 (3.7%) | 0 (0.0%) | 12 (4.4%) | 10 (3.7%) |
| Aspirin | 195 (71.7%) | 61 (22.4%) | 256 (94.1%) | 256 (94.1%) |
| Dual antiplatelet therapy | 111 (40.8%) | 145 (53.3%) | 256 (94.1%) | 256 (94.1%) |
| Unfractionated heparin | 0 (0.0%) | 153 (56.3%) | 0 (0.0%) | 153 (56.3%) |
| Bivalirudin | 0 (0.0%) | 4 (1.5%) | 0 (0.0%) | 4 (1.5%) |
| Enoxaparin | 115 (42.3%) | 0 (0.0%) | 0 (0.0%) | 115 (42.3%) |
| Warfarin | 6 (2.2%) | 2 (0.7%) | 2 (0.7%) | 8 (2.9%) |
| Dabigatran | 2 (0.7%) | 16 (5.9%) | 14 (5.1%) | 10 (3.7%) |
| Oral AntiXa | 8 (2.9%) | 2 (0.7%) | 6 (2.2%) | 8 (2.9%) |
PCI: percutaneous cardiovascular intervention.